Ceftaroline fosamil: drug profile and clinical data.

Abstract

Several studies have shown that the rates of resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), hetero-VISA, and penicillin-resistant Streptococcus pneumoniae have witnessed a substantial global increase. Ceftaroline fosamil is the prodrug form of ceftaroline, a new cephalosporin active against resistant Gram-positive pathogens and common Gram-negative organisms that do not produce extended-spectrum-β-lactamases and do not express AmpC. Ceftaroline fosamil was found to be effective and well-tolerated for the treatment of complicated skin and skin-structure infections and community-acquired bacterial pneumonia compared with standard therapy. The drug has recently been granted US FDA approval for both indications.

• Authors: Zeina A Kanafani
• Journal: Future microbiology (Future Microbiol) Vol. 6 Issue 1 Pg. 9-18 (Jan 2011) ISSN: 1746-0921 [Electronic] England
• PMID: 21162631 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• beta-Lactamases

Topics

• Animals
• Anti-Bacterial Agents (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Cephalosporins (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Community-Acquired Infections (drug therapy, microbiology)
• Drug Resistance, Bacterial
• Gram-Negative Bacteria (drug effects)
• Gram-Positive Bacteria (drug effects)
• Humans
• Mice
• Microbial Sensitivity Tests
• Pneumonia, Bacterial (drug therapy)
• Rabbits
• Skin Diseases, Bacterial (drug therapy)
• beta-Lactamases (genetics, metabolism)
• Ceftaroline